While the activation of the NR4A2-VGF axis might counteract acute challenges, its persistent activation appears to be a maladaptive response to chronic axonal damage, disruption of the TCA cycle, and oxidative phosphorylation in EAE and MS. Here, NR4A2 is linked to myeloid sarcoma.